Skip to main content

Search

Global Public Health

Global Public Health

Janssen exists to help resolve some of the most important unmet medical needs of our time. We use our scientific expertise to transform entire disease areas and make significant contributions to global human health.

Janssen has invested £10 million in a UK government-led global Dementia Discovery Fund that will support innovative research to help find new ways to prevent and treat dementia and Alzheimer’s disease. This brings together industry, governments and non-profit organisations to create new sources of investment to support this research 1.

We are continuing to support the containment of Ebola, to save lives and protect the health of those at risk. Janssen has developed a preventative Ebola vaccine which is currently undergoing a clinical trial, led by the Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics 2

At Janssen, we are also working with the not-for-profit Drugs for Neglected Diseases initiative (DNDi) on the pre-clinical programme for a potential new treatment against parasites that cause elephantiasis and river blindness — two of the most difficult-to-treat neglected tropical diseases (NTDs).

International Health Partners (IHP)- Medicines for those in need

We are proud to partner with International Health Partners (IHP) to donate products to crisis-hit communities and help eradicate suffering caused by poor access to medicine. IHP help vulnerable people by overseeing, co-ordinating and delivering strategic medical product donations to those in desperate need of healthcare around the world.

 

 

 

 

References:

1. Dementia Discovery Fund (2015) Launch of Dementia Discovery Fund.

2. Reuters (2018)  Oxford Vaccines Funding Press Release.